Are Orforglipron and Tesofensine Peptides or Drugs?

Receptor target does not define molecular class

Semaglutide and tirzepatide are peptides because their active structures contain ordered amino-acid backbones with engineered residues and lipid side chains. They are characterized using peptide-aware tools such as intact-mass deconvolution, peptide mapping and related-sequence impurity analysis. Orforglipron is described in the scientific and regulatory literature as a non-peptide, small-molecule GLP-1 receptor agonist. It reaches the same receptor family by a different chemical architecture. Calling it a “GLP-1 peptide” because it activates GLP-1R is like calling every enzyme inhibitor a protein.

Tesofensine is also not a peptide. The FDA’s Global Substance Registration System classifies it as a chemical and records the formula C17H23Cl2NO with a molecular weight of about 328.28. Its defined stereochemistry and dichlorophenyl-containing small-molecule structure bear no resemblance to an amino-acid oligomer. Salt forms such as citrate or tartrate may appear in commerce, which changes the formula weight of the supplied substance but does not turn it into a peptide.

The distinction should be encoded in the database at three levels: molecular class, pharmacologic mechanism and regulatory status. These fields answer different questions. “GLP-1 receptor agonist” is a mechanism label; “small molecule” is a structural label; approval or investigational status is a time- and jurisdiction-dependent regulatory label. One cannot replace another.

Why peptide test packages fail on these compounds

Amino-acid analysis and peptide sequencing are irrelevant primary identity methods for orforglipron and tesofensine. Their LC-MS spectra normally center on singly charged molecular ions rather than the multiply charged envelopes typical of 4–5 kDa lipidated peptides. Small-molecule impurity control must consider synthetic intermediates, regioisomers, stereoisomers, residual catalysts, inorganic residues and salt/solvate state. A generic peptide RP-HPLC gradient may separate the main component, but it is not automatically stability-indicating or selective for those risks.

Chiral purity deserves explicit attention. A mass match cannot distinguish stereoisomers, and a conventional achiral HPLC purity result may not separate them. NMR, chiral chromatography, accurate-mass MS, IR or other orthogonal techniques may be used according to the compound and specification. Residual-solvent and elemental-impurity assessments should follow the actual synthetic route. For a salt, assay calculations must state whether the result is on an anhydrous, solvent-free, free-base or as-is basis.

• Reject any COA that supplies an amino-acid sequence for orforglipron or tesofensine.
• Verify molecular formula, exact form, stereochemistry, counterion and theoretical mass against an authoritative substance record.
• Require identity by at least two appropriate, orthogonal techniques for reference-material qualification.
• Review chiral purity separately from achiral area purity where stereochemistry is critical.
• Confirm quantitative assay, water/solvate state, residual solvents and elemental impurities rather than treating HPLC area as content.
• Keep mechanism claims, molecular classification and current regulatory status in separate database fields.

A common reseller shortcut is to copy a peptide template, leaving fields for sequence, N-terminal modification and “lyophilized peptide purity.” Another is to use “oral peptide” as an SEO phrase for any compound discussed alongside injectable incretin analogues. Orforglipron’s oral small-molecule design is precisely what distinguishes it from peptide GLP-1 agonists. The wording should be corrected in titles, schema markup, category breadcrumbs and product specifications.

Storage, sourcing and compliance consequences

Do not assign peptide storage conditions by analogy. Small molecules may have different sensitivity to humidity, light, oxidation, crystal form conversion or salt disproportionation. Use compound- and form-specific stability data. A crystalline salt and amorphous free base can differ in water uptake and dissolution behavior even when both yield the same active moiety in MS.

Procurement should also avoid the phrase “custom peptide synthesis” for these targets. They require small-molecule medicinal chemistry capabilities, route controls and impurity standards. A peptide manufacturer may also operate a qualified small-molecule facility, but the capability must be demonstrated rather than inferred from its peptide catalog.

RUO labeling does not cure inaccurate identity or unauthorized claims. A research supplier should state the chemical class correctly, provide an unambiguous structure and form, and avoid presenting investigational material as an approved therapeutic. Regulatory status can change, so editors should verify it at publication and review dates through current regulator databases. Substance-registration records are useful for identity but may explicitly warn that database inclusion does not imply approval.

Primary starting points include authoritative chemical records for tesofensine and peer-reviewed structural work describing non-peptide GLP-1 receptor agonists such as orforglipron. The FDA explains that pharmacologic class can reflect mechanism, physiologic effect and chemical structure; for a technical database, retaining those dimensions separately prevents the common error at issue here.

Orforglipron and tesofensine belong in a metabolic research database only if they are clearly marked as non-peptide comparators. They should not inflate a peptide count, inherit peptide QA fields or be represented by invented sequences. This page is for chemical classification, procurement and Research Use Only documentation. It provides no dosing, treatment or human-use guidance.

Primary records and verification routes

Use the primary paper, current regulator record or lot-linked analytical file for the specific claim it supports. Search results are routes to evidence, not evidence by themselves.